Last Updated : September 5, 2024
Details
Generic Name:
ruxolitinib
Project Status:
Pending
Therapeutic Area:
Nonsegmental vitiligo
Manufacturer:
Incyte Biosciences Canada Corporation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0835-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 5, 2024